首页> 美国卫生研究院文献>Frontiers in Veterinary Science >Estimating the Efficacy of a Commercial Phase I Inactivated Vaccine in Decreasing the Prevalence of Coxiella burnetii Infection and Shedding in Red Deer (Cervus elaphus)
【2h】

Estimating the Efficacy of a Commercial Phase I Inactivated Vaccine in Decreasing the Prevalence of Coxiella burnetii Infection and Shedding in Red Deer (Cervus elaphus)

机译:估计商业第一阶段灭活疫苗在减少马鹿柯氏杆菌感染和红鹿脱落中的功效。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The red deer (Cervus elaphus) is a relevant reservoir for Coxiella burnetii in Iberia. C. burnetii genotypes that infect red deer also infect humans and domestic animals. Integrated control approaches that target both domestic and wild ruminants are, therefore, required to reduce C. burnetii infection risks in Iberia, especially in wildlife–livestock–human interaction scenarios. The aim of this field experiment was to test the efficacy of an inactivated phase I vaccine [Inactivated phase I vaccine (IPIV); Coxevac®] when used to control C. burnetii shedding prevalence and burden in red deer as a tool to prevent transmission to livestock and humans. A semi-extensively bred red deer population in which C. burnetii is endemic was used as a model of the Iberian context. Around 75% of the reproductive hinds (>1 year old; N = 441) in the population were first vaccinated early in 2012 and were then revaccinated 3 weeks later; they were subsequently revaccinated biannually until January 2014. 75% of the yearling females left as replacement in 2012 and 2013 were vaccinated in June and revaccinated thereafter following the same protocol. 25% of the population, including the replacement females, was kept as a control group throughout the study. Changes in the humoral immune response after vaccination were estimated by analyzing sera collected at 10 different times between January 2011 and January 2015. The vaccinated and control hinds were surveyed at 2.5, 3.5, and 4.5 months after calving in 2012, 2013, and 2014 to collect vaginal swabs, milk, and feces. The presence and burden of C. burnetii DNA in swabs, milk, and feces was evaluated by means of real-time PCR. Vaccination induced high antibody prevalence and levels. The proportion of animals shedding C. burnetii in vaginal secretions and milk did not change over time in the vaccination group with respect to the control group. In contrast, there was a significant reduction in the proportion of deer shedding C. burnetii in feces in both the vaccinated and control groups. The decrease in the proportion of fecal shedders coincided with a significant reduction in the incidence of infection of non-vaccinated yearling females in the population. This finding suggests that long-term vaccination with IPIV could reduce environmental contamination with C. burnetii and control transmission, perhaps making this a promising tool with which to control C. burnetii in red deer in the future.
机译:马鹿(Cervus elaphus)是伊比利亚(Iberia)伯氏柯氏杆菌的相关储藏库。感染马鹿的伯氏梭菌基因型也感染人和家畜。因此,需要针对家养和野生反刍动物的综合控制方法,以减少伊比利亚,特别是在野生生物-畜牧-人与动物互动的情况下伯氏梭菌的感染风险。该现场实验的目的是测试一种灭活的I期疫苗[灭活的I期疫苗(IPIV); Coxevac ®]可以用来控制马尾念珠菌减少马鹿的流行和负担,以此作为防止传播给牲畜和人类的工具。一个半广泛繁殖的马鹿种群(其中伯氏梭菌为地方病)被用作伊比利亚环境的模型。人口中约有75%的后代(> 1岁; N = 441)在2012年初进行了疫苗接种,然后在3周后进行了疫苗接种。随后每半年两次对她们进行一次疫苗接种,直到2014年1月。2012年和2013年作为替代品的一岁雌性的75%在六月进行了疫苗接种,之后按照相同的方案进行了疫苗接种。在整个研究过程中,将25%的人口(包括替代女性)作为对照组。通过分析2011年1月至2015年1月在10个不同时间采集的血清来估计疫苗接种后的体液免疫反应的变化。在2012、2013和2014年产犊后2.5、3.5和4.5月对接种和对照后代进行调查。收集阴道拭子,牛奶和粪便。通过实时PCR评估拭子,牛奶和粪便中伯氏梭状芽胞杆菌DNA的存在和负担。疫苗接种导致高抗体流行率和水平。相对于对照组,接种组中阴道分泌物和牛奶中脱落伯氏梭菌的动物比例没有随时间变化。相反,在疫苗接种组和对照组中,脱落在粪便中的伯氏梭菌的比例均显着降低。粪便流失者比例的降低与人群中未接种疫苗的一岁雌性动物的感染率显着降低同时发生。这一发现表明,长期接种IPIV疫苗可以减少伯氏梭菌对环境的污染并控制传播,也许这将成为将来控制马鹿伯氏梭菌的有前途的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号